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Abstract. Differentiation syndrome (DS), formerly known as retinoic acid syndrome, is the main 
life-threatening complication of therapy with differentiating agents (all
or  arsenic  trioxide  [ATO])  in  patients  with  acute  promyelocytic  leukemia  (APL).  The 
differentiation of leukemic blasts and promyelocytes induced by ATRA and/or ATO may lead to 
cellular  migration,  endothelial  activation,  and  release  of  interleukins  a
responsible  of  tissue  damage. Roughly  one  quarter  of  patients  with  APL  undergoing  induction 
therapy will develop the DS, characterized by unexplained fever, acute respiratory distress with 
interstitial pulmonary infiltrates, and/or a va
failure. Although the development of the DS, particularly of the severe form, is still associated with 
a significant increase in morbidity and mortality during induction, the early administration of hig
dose dexamethasone at the onset of the first symptoms seems likely to have dramatically reduced 
the mortality rate of this complication. In this article, we will review the clinical features, incidence, 
prognostic factors, management, and outcome of the 
will make focus in the experience of the three consecutive Programa Español de Tratamientos en 
Hematología trials (PETHEMA LPA96, LPA99, and LPA2005), in which more than one thousand 
patients were treated with ATRA plus idarubicin for induction.
Introduction. Differentiation syndrome (DS), formerly 
known  as  retinoic  acid  syndrome,  is  the  main  life
threatening  complication  of 
differentiating agents (all-trans retinoic acid [ATRA] 
or  arsenic  trioxide  [ATO])  in  patients  with  acute 
promyelocytic  leukemia  (APL).  This  complication 
typically  occurs  during  induction  therapy  with 
; Open Journal System 
EDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES
www.mjhid.org ISSN 2035-3006
The  Differentiation  Syndrome  in  Patients  with  Acute  Promyelocytic  Leukemia: 
he Pethema Group and Review of the Literature.
University Hospital La Fe, València, Spain.
Miguel A. Sanz. Hematology Department. University Hospital La Fe, València. Department of 
Medicine, University of València. Bulevard Sud S/N, 46026 València, Spain. Tel:+34 961245875; F
have declared that no competing interests exist.
e2011059, DOI 10.4084/MJHID.2011.059
http://www.mjhid.org/article/view/9536
This  is  an  Open  Access  article  distributed  under  the  terms  of  the  Creative  Commons  Attribution  License
http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, 
the original work is properly cited.
Differentiation syndrome (DS), formerly known as retinoic acid syndrome, is the main 
threatening complication of therapy with differentiating agents (all-trans
or  arsenic  trioxide  [ATO])  in  patients  with  acute  promyelocytic  leukemia  (APL).  The 
differentiation of leukemic blasts and promyelocytes induced by ATRA and/or ATO may lead to 
cellular  migration,  endothelial  activation,  and  release  of  interleukins  a
responsible  of  tissue  damage. Roughly  one  quarter  of  patients  with  APL  undergoing  induction 
therapy will develop the DS, characterized by unexplained fever, acute respiratory distress with 
interstitial pulmonary infiltrates, and/or a vascular capillary leak syndrome leading to acute renal 
failure. Although the development of the DS, particularly of the severe form, is still associated with 
a significant increase in morbidity and mortality during induction, the early administration of hig
dose dexamethasone at the onset of the first symptoms seems likely to have dramatically reduced 
the mortality rate of this complication. In this article, we will review the clinical features, incidence, 
prognostic factors, management, and outcome of the DS reported in the scientific literature. We 
will make focus in the experience of the three consecutive Programa Español de Tratamientos en 
Hematología trials (PETHEMA LPA96, LPA99, and LPA2005), in which more than one thousand 
TRA plus idarubicin for induction.
Differentiation syndrome (DS), formerly 
known  as  retinoic  acid  syndrome,  is  the  main  life-
threatening  complication  of  therapy  with 
retinoic acid [ATRA] 
or  arsenic  trioxide  [ATO])  in  patients  with  acute 
promyelocytic  leukemia  (APL).  This  complication 
typically  occurs  during  induction  therapy  with 
differentiating  agents  while  leukemic  blast
massively  present,  but  it  never  take  place  during 
consolidation  or  maintenance  therapy  for  APL.  This 
syndrome is characterized by unexplained fever, acute 
respiratory  distress  with  interstitial  pulmonary 
infiltrates,  and/or  a  vascular  capillary leak 
leading to acute renal failure.
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Differentiation syndrome (DS), formerly known as retinoic acid syndrome, is the main 
trans retinoic acid [ATRA] 
or  arsenic  trioxide  [ATO])  in  patients  with  acute  promyelocytic  leukemia  (APL).  The 
differentiation of leukemic blasts and promyelocytes induced by ATRA and/or ATO may lead to 
cellular  migration,  endothelial  activation,  and  release  of  interleukins  and  vascular  factors 
responsible  of  tissue  damage. Roughly  one  quarter  of  patients  with  APL  undergoing  induction 
therapy will develop the DS, characterized by unexplained fever, acute respiratory distress with 
scular capillary leak syndrome leading to acute renal 
failure. Although the development of the DS, particularly of the severe form, is still associated with 
a significant increase in morbidity and mortality during induction, the early administration of high-
dose dexamethasone at the onset of the first symptoms seems likely to have dramatically reduced 
the mortality rate of this complication. In this article, we will review the clinical features, incidence, 
DS reported in the scientific literature. We 
will make focus in the experience of the three consecutive Programa Español de Tratamientos en 
Hematología trials (PETHEMA LPA96, LPA99, and LPA2005), in which more than one thousand 
differentiating  agents  while  leukemic  blasts  are 
massively  present,  but  it  never  take  place  during 
consolidation  or  maintenance  therapy  for  APL.  This 
syndrome is characterized by unexplained fever, acute 
respiratory  distress  with  interstitial  pulmonary 
infiltrates,  and/or  a  vascular  capillary leak  syndrome 
leading to acute renal failure.
1 This clinical picture may Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
be  due  to  cellular  migration,  endothelial  activation, 
release  of  interleukins,  and  vascular  factors
2-4 
responsible  for  tissue  damage.  Although  a  “cytokine 
storm”  has  been  described  coinciding  with 
differentiation of blasts, the underlying etiopathogenic 
mechanisms  of  this  syndrome  remain  partially 
unknown. The diagnosis of the DS is mainly based on 
clinical  and  radiological  features  in  the  context  of 
induction therapy of APL with differentiating agents, 
and  it  usually  requires  the  exclusion  of  alternative 
causes that could explain the signs and symptoms of 
the  syndrome.  Early  therapeutic  or  preemptive 
interventions  to  counteract  the  DS  using  intravenous 
corticoids  and  other  supportive  measures  should  be 
instituted at the onset of the first suggestive signs and 
symptoms  and  before  exclusion  of  other  possible 
causes.  The  administration  of  high-dose 
dexamethasone  at  the  onset  of  the  first  symptoms 
appear to reduce the DS-related mortality to 1% or less 
in the most recent trials.
5-7
In the  present  article, we  will  review  the  clinical 
features,  incidence,  prognostic  factors,  management, 
and outcome of the DS. We will mainly focus on the 
experience of three consecutive trials of the Programa 
Español de Tratamientos en Hematología (PETHEMA 
LPA96, LPA99, and LPA2005), in which more than 
one thousand adult and pediatric patients were treated 
with  ATRA  plus  idarubicin  for  induction  (AIDA 
regimen), as well as on a review of the literature.
Diagnosis of the DS. The first description of DS by 
Frankel  et  al,
1 was  based  on  the  observation  of  a 
distinctive  clinical  syndrome  in  9  out  of  35  APL 
patients  who  were  treated  with  ATRA  alone  for 
induction therapy. All of them had developed a variety 
of  signs  and  symptoms  characterized  primarily  by 
fever,  respiratory  distress,  weight  gain,  and  a  chest 
radiograph  showing  pleural  effusion  and  pulmonary 
infiltrates.  Other  clinical  features,  such  as  peripheral 
edema,  unexplained  hypotension,  renal  insufficiency, 
hyperbilirubinemia, and pericardial effusion, were also 
associated with the syndrome with variable frequency. 
Although  most  subsequent  studies  reporting  the 
incidence  and  clinical  characteristics  of  DS  in  APL 
refer to Frankel’s definition, it must be noted that in 
several  representative  reports  there  is  a  variable 
interpretation of the original description. The reports of 
the GIMEMA-AIEOP 0493-AIDA trial,
5 the European 
APL 93 trial,Errore. Il segnalibro non è definito. and the 
National Cancer Institute Protocol 0129,
8 used different 
criteria  for  the  diagnosis  of  the  DS  leading  to  a 
different reported incidence, ranging from 2% to 27%. 
The  PETHEMA  group  has  recently  reported  the 
incidence  and  characteristics  of  DS  in  two  large 
series
9,10 of patients undergoing induction therapy with 
the AIDA regimen using the same definition criteria, 
which were based on the presence of at least two of the 
following signs and symptoms: dyspnea, unexplained 
fever,  weight  gain  greater  than  5  kg,  unexplained 
hypotension,  acute  renal  failure,  and,  particularly,  a 
chest  radiograph  demonstrating  pulmonary  infiltrates 
or  pleuropericardial  effusion.  No  single  sign  or 
symptom  was  considered  sufficient  to  diagnose  the 
syndrome,  and  any  alternative  cause  explaining  the 
clinical clinical features should be ruled out. For some 
authors, patients with an alternative cause explaining 
the  syndrome  have  been  classified  as  indeterminate 
DS,  with  a  frequency  varying  from  4%  to  19%,
8,11
while others have used the term indeterminate DS for 
patients manifesting only a partial symptom complex 
(i.e., patients with less than 4 clinical criteria of DS).
5
In the PETHEMA studies, a severity gradation of the 
DS for predicting outcomes was established, using the 
terms moderate and severe DS according to the number 
of  clinical  criteria  fulfilled.  Thus,  patients  with  4  or 
more of the above signs and symptoms were classified 
as having severe DS, while those with less than 4 signs 
or symptoms were considered to have moderate DS. In 
the PETHEMA series, in roughly 5% of the patients 
with possible DS according to the predefined criteria, 
an unambiguous diagnosis of DS could not be made 
and therefore they were not considered as having the 
syndrome. This was due to the presence of concurrent 
medical  problems  that  could  explain  the  clinical 
manifestations,  such  as  pulmonary  hemorrhage, 
pneumonia, congestive heart failure, renal failure, and 
septic shock.
9
The  diagnosis  of  the  DS  is  mostly  based  on  the 
above  defined  clinical  and  radiological  criteria  and 
supported by the striking response to early therapy with 
intravenous  corticosteroids.  The  use  of  invasive 
diagnostic  techniques,  such  as  bronchoscopy  and 
bronchoalveolar lavage or lung biopsy, is not usually 
required in patients with suspected DS and respiratory 
distress  with  lung  infiltrates.  Nevertheless,  when  the 
clinical  course  is  not  satisfactory  despite  receiving 
appropriate  therapy,  or  when  the  patient needs 
orotracheal intubation for mechanical ventilation,  the 
bronchoscopy  and  bronchoalveolar  lavage  could  be 
useful  to  exclude  a  pulmonary  haemorrhage  or  an 
infection causing the respiratory distress. Lung biopsy 
is  usually  contraindicated  in  patients  with  DS  that 
frequently  shows  concomitant  severe 
thrombocytopenia and coagulation disorders leading to 
an  extremely  high  risk  of  bleeding  complications. 
When performed, in life or in postmortem examination, 
the  major  hystologic  findings  of  lung  biopsies  are 
interstitial  infiltration  with  maturing  granulocytic 
cells,
1,8 diffuse  alveolar  damage,  intraalveolar 
haemorrhage, and small vessels inflammation.
4,12Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
Clinical Manifestations of the DS. The typical signs 
and symptoms of the differentiation syndrome include 
fever, hypotension, dyspnea, weight gain of more than 
5  kg,  and  pulmonary  infiltrates  in  chest  radiograph. 
The  frequency  of  these  signs  and  symptoms  varies 
within the different reports, ranging from 59% to 95% 
for dyspnea, 53% to 74% for fever, 40% to 81% for 
pulmonary  infiltrates,  and  12%  to  39%  for 
hypotension. In a PETHEMA study that analyzed 739 
patients included in the LPA96 and LPA96 trials, the 
most  frequent  clinical  manifestations  of  DS  were 
dyspnea, pulmonary infiltrates, unexplained fever, and 
weight gain of more than 5 kg (Table 1). Other clinical 
manifestations can be associated with the DS, such as 
peripheral  edema  (53%  to  81%),
6,9  musculoskeletal 
pain,
1,8,13,14 acute  febrile neutrophilic  dermatosis 
(Sweet´s  syndrome),
15 and  hyperbilirubinemia.
1,9
However,  these  manifestations  are  generally  not 
considered  in  diagnosis  for  DS.  In  addition,  it  is 
frequently  observed  an  increased  WBC  count  at  the 
onset or during the development of the DS which may 
support  the  diagnosis.
8,11,14 However,  many  patients 
will  develop  a  full-blown  DS  in  the  absence  of  an 
increase  in  the  WBC  (e.g.,  during  the  neutropenic 
phase  after  chemotherapy  or  ATO).  Therefore,  the 
WBC count should not be considered as a diagnostic 
criterion of DS. 
Abnormal  findings  in  chest  radiography  or 
computerized tomography are very common during the 
course of DS (up to 81% in the severe forms).
9 These 
findings  will  usually  affect  both  the  right  and  left 
lungs, reflecting that DS is a systemic process derived 
from  diffuse  alterations  in  the  blood  homeostasis 
(endothelial  membrane  injury  by  cytokines  release 
and/or  granulocyte  infiltration).  Treatment  of  DS 
should not be postponed until after having an abnormal 
chest radiograph since roughly 40 percent of patients 
with  DS  have  a  normal  chest  radiograph  at 
presentation. The typical findings on a chest radiograph
Table 1. Signs and symptoms of moderate and severe DS during 
induction therapy with AIDA regimen in APL patients enrolled in 
the PETHEMA LPA96 and LPA9 trials (n=739).
Clinical Signs and 
Symptoms
Frequency of the signs and 
symptoms according to the type of 
DS
Moderate 
DS (n=90)
Severe DS 
(n=93)
P value Nº. (%) Nº. (%)
Dyspnea 53 (59) 88 (95) <0.001
X-ray Pulmonary Infiltrates 34 (38) 75 (81) <0.001
Edema 48 (53) 75 (81) 0.001
Unexplained Fever 48 (53) 69 (74) 0.003
Weight Gain > 5 kg 34 (38) 63 (68) <0.001
Pleural Effusion 24 (27) 54 (58) <0.001
Renal Failure 8 (9) 43 (46) <0.001
Hypotension 11 (12) 36 (39) <0.001
Pericardial Effusion 10 (11) 21 (23) 0.04
are  interstitial  infiltrates  (i.e.,  septal  lines  and 
peribronchial cuffing,  ground  glass  opacity)  and 
pleural effusion. It is also frequent to find an increased 
cardiothoracic  ratio  (up  to  87%)  and  parenchymal 
consolidation  (47%)  with  or  without  air 
bronchogram.
12 It should be noted that the differential 
diagnosis  of  such  imaging  pictures  includes  a  wide 
variety  of  pathological  conditions  that  could  also 
explain  the  clinical  picture  and  that  should  be 
consequently excluded to make the definitive diagnosis 
of DS. As an example, in patients with heart congestive 
failure  or  left  ventricle  insufficiency  (pulmonary 
edema) increased cardiothoracic ratio, septal lines, and 
pleural  effusion  can  be  also  observed  in  the  chest 
radiography.  An  echocardiography  showing  ventricle 
dysfunction and/or prior history of cardiac disease will 
support the  diagnosis  of heart failure instead of DS. 
Also,  parenchymal  consolidation  or  interstitial 
infiltrates can be explained by pneumonia in a febrile 
neutropenic  patient.  In  such  cases,  microbiologic 
isolates,  patterns  of  fever,  further  response  to 
intravenous  dexamethasone  or  antibiotics,  and  the 
clinical and radiological course will help in making a 
diagnosis.  Some  patients  developing  pulmonary 
haemorrhage  will  show  areas  of  consolidation  and 
diffuse  ground  glass  opacities  in  the  chest 
computerized tomography or radiography that may be 
indistinguishable  from  those  seen  in  patients  with 
severe  DS.  Of  note,  an  association  between  the 
occurrence  of  DS  and  disseminated  intravascular 
coagulopathy  and  haemorragic  syndrome,  including 
pulmonary  bleeding,  has  been  reported.
9,15  These 
finding suggests that, at least in some cases, DS and 
pulmonary haemorrhage may occur  concomitantly as 
part of the same pathogenic process. 
Pericardial  effusion  is  a  less  frequently  reported 
manifestation of the DS (less than 20% of cases). We 
should  highlight  that  in  many  cases  this  sign  is  not 
detected  in  a  simple  chest  radiography,  requiring  a 
computerized tomography or an echocardiography. In 
some  patients  the  DS  can  be  accompanied  by 
electrocardiographic  and  laboratory  signs of 
myopericarditis,  with  or  without  radiological 
pericardial  effusion,  leading  to  transient  cardiac 
ventricle  dysfunction.
16 In  these  rare  cases,  the 
differential  diagnosis  between  DS  and  acute  cardiac 
toxicity  induced  by  anthracyclines  might  be 
challenging. The diagnosis of DS can be supported by 
the fact that, in the context of differentiation therapy, 
myocardial dysfunction will disappear after induction 
phase once the DS is resolved.  
Timing of the DS. The median day of onset of clinical 
manifestations of the DS has been reported in a range 
of  7  to  12  days  after  starting  differentiation  therapy Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
(Table 2).
17-19 In a recent PETHEMA study,
9 the DS 
occurred at a median of 12 days after starting ATRA 
treatment  (range,  0-46  days).  Severe  DS  occurred 
earlier (median, 6 days) than moderate DS (median, 15 
days).
9 This study showed that the presentation of the 
DS  follows  a  bimodal  pattern  with  47%  of  patients 
developing clinical manifestations within the first week
(early DS) and 48% developing symptoms during the 
third week or beyond after starting ATRA (late DS). A 
bimodal time distribution of the peak incidence of DS 
was observed in both moderate and severe DS (Figure 
1). It should  be noted that cases of early severe DS 
required  mechanical  ventilation  or  dialysis  more 
frequently and were associated with a higher mortality 
during  induction  (up  to  40%)  compared  with  those 
occurring  during  the  third  week  or  beyond.  Early 
severe DS was characterized by a higher frequency of 
pulmonary infiltrates and weight gain, probably related 
to an initial rise in leukocytosis and fluid overload. The 
PETHEMA study showed that the number of packed 
red blood cells, platelets, and fresh frozen plasma units 
transfused  were  significantly higher  in  patients  with 
early severe DS compared with those with late severe 
DS.  In  contrast,  hypotension,  unexplained  fever, 
pericardial  effusion,  and  renal  failure  were  more 
frequent in late severe DS. We should emphasize that 
in this situation distinguishing between DS and other 
clinical  complications,  particularly  sepsis,  may  be 
difficult.  Therefore,  in  these  cases,  treatment  of  DS 
should  be  complemented  with  therapeutic  measures 
addressing alternative diagnoses that could also explain 
the symptoms (e.g., infections). 
Incidence of the DS. The reported incidence of DS in 
APL  patients  treated  with  standard  doses  of  ATRA 
ranges from 2% to 27% (Table 2), while in patients 
treated with ATO ranges from 7% to 31%.
14,20-23 This 
wide  variation is  at  least partially due  to  the  use  of 
different  diagnostic  criteria  employed  in  reported 
studies. In addition, the effects on the incidence and 
severity  of  the  syndrome  due  to  differences  in 
induction  therapy  and  preemptive  and  supportive 
measures should also be considered. The DS may also 
occur in patients with relapsed APL receiving salvage
Figure 1.
therapy with ATRA, ATO, or the combination of both 
agents.
24 The risk of developing DS in  patients with 
advanced disease is not well known, but it is likely that 
patients presenting with molecular relapse may have a 
lower risk of developing this complication. It should be 
noted that DS never develops during consolidation or 
maintenance therapy, since this syndrome depends on 
the  presence  of  leukemic  promyelocytes  and  the 
release of cytokines by these cells.
The most likely explanation for different incidence 
rates  reported  of  DS  in  different  studies  could  be 
explained by the lack of consensus in the definition, 
grading,  and  classification  of  the  syndrome.  The 
PETHEMA  group  has  analyzed  the  incidence  and 
severity  of  DS  in  three  subsequent  studies  (LPA96, 
LPA99,  and  LPA2005  trials)
9,10 using  induction 
therapy with AIDA regimen. With the aforementioned 
criteria  for  the  definition  and  gradation  of  DS  an 
overall incidence of 24.8% was found in the LPA96 
and LPA99 trials (12.6% severe and 12.2% moderate 
forms),  compared  with  28.5%  in  the  LPA2005  trial 
(12.1% severe and 16.3% moderate). These differences 
in the incidence were not significant. The GIMEMA 
group,
5 also using the AIDA regimen, reported a very 
low  2.5%  incidence  of  DS  (6  of  240  patients). 
However, their definition of DS was notably different 
to other studies. They established a diagnosis of severe 
DS according to the presence of 5 of the 7 signs and 
symptoms  as  originally  described  by  Frankel  et  al.
1
Interestingly, when the same definition was applied to 
the PETHEMA series, a similar incidence of 2.6% was 
found.  In other  studies  of  concurrent  ATRA  plus 
chemotherapy regimens, a greater incidence of DS has 
been  reported  (11%  to  16%).  Again,  the  diagnostic 
criteria for the syndrome were often not defined
25,26 or 
were less strict compared with the GIMEMA study.
On  the  other  hand,  the  concurrent  use  of 
chemotherapy with ATRA in some but not all studies 
has probably determined differences in the incidence 
and  severity  of  DS.  In  this  respect,  the  results  of  a 
randomized  study  that  focused  on  patients  with  low 
WBC  counts  (≤ 5  ×  10
9/L),
6 and  several 
nonrandomized studies
25,26 strongly suggested that the 
incidence may be lower when ATRA is administered 
concurrently with induction chemotherapy.
Regarding  the  incidence  of  DS  in  APL  patients 
treated  with  ATO-based  regimens  for  induction 
therapy, it seems that it may be similar to that reported 
in  patients  receiving  ATRA-containing  regimens. 
However, similarly to ATRA therapy alone, there is an 
apparent higher incidence and severity of the DS when 
induction  therapy  consists  of  ATO therapy  alone.
14
Consequently,  the  simultaneous  administration  of 
cytotoxic  agents  (i.e.,  hydroxyurea,  cytarabine, 
anthracyclines) could be recommended when induction Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
Table 2. Main publications reporting the incidence and outcome of DS in patients with APL managed with ATRA.
First author 
& year 
(reference)
Induction 
therapy DS prevention
Number 
of 
patients
Indeterminate 
DS
Number 
of DS 
criteria 
needed
$
Incidence 
of DS
Median 
day of 
onset of 
the DS
Death by 
DS
Risk 
factors for 
DS (n, %) n   (%) n (%)
Frankel, 
1992 (1) ATRA None 35 No 5 of 7 9 (26) 10 3 (9) No
Vahdat, 
1994 (11) ATRA None 78 15 (19) 4 of 4 21 (27) NR 7 (9)
WBC 
peak, 
CD13+
Cortes, 
1994 (18) ATRA
CT if blasts + 
promyelocytes >10 
x10
9/L
17 NR NR 4 (24) NR 1 (5) No
Avvisati, 
1995 (19) AIDA None 20 NR 2 of 3 2 (10) 10 1 (5) NR
Mandelli, 
1997 (5) AIDA None 240 NR 5 of 5 17 (8) NR 1 (0.2) NR
Wiley, 
1997 (34) ATRA
CT if WBC > 1 
x10
9/L, PDN if 
WBC < 1x10
9/L
22 NR NR 2 (9) NR 1 (4) No
De Botton, 
1998 (6)
ATRA 
followed by 
CT or 
ATRA+CT
CT if WBC >5 
x10
9/L at 
presentation, if >6, 
>10, >15 x10
9/L on 
day 5, 10 and 15
413 NR 3 of 7 64 (15) 7 5 (1.2) No
Tallman, 
2000 (8) ATRA
Hydrea if baseline 
WBC > 1 x10
9/L or 
>30 x10
9/L during 
induction
167 7 (4) 2 of 7 44 (26) 11 2 (1.2) No
Montesinos, 
2008 (9) AIDA
DXM if WBC >5 
x10
9/L (LPA96) or 
PDN 0.5 mg/kg 
(LPA99)
739 33 (5) 2 of 7 183 (25) 12 10 (1.4)
Creatinine 
> ULN, 
WBC >5 
x10
9/L, 
LPA96
Sanz, 
2009 (10) AIDA DXM if WBC >5 
x10
9/L 372 9 (3) 2 of 7 106 (28) NR 4 (1.1) NR
Jeddi, 
2009 (29)
AIDA or 
ATRA+CT
None or PDN 0.5 
mg/kg 42 NR 3 of 7 10 (24) NR 6 (14)
Body 
mass 
index 
>35*
Abbreviations: DS: differentiation syndrome, ATRA: all-transretinoic acid, AIDA: ATRA plus idarubicine, CT: chemotherapy, WBC: white 
blood cells, DXM: dexamethasone, PDN: prednisone, ULN: upper laboratory normal values, NR: not reported. $ According to the following 
criteria:  dyspnea,  unexplained  fever,  weight  gain  greater  than  5  kg,  unexplained  hypotension,  acute  renal  failure,  chest  radiograph 
demonstrating pulmonary infiltrates, and pleuropericardial effusion. *Predictive for all ATRA-derived complications 
with  ATO  in  patients  presenting  with 
hyperleukocytosis or  in  those  developing  this 
complication later.
20,23,24
Prognostic  Factors  for  the  Development  of  DS. 
Apart from a peak WBC count frequently observed at 
the onset of DS, very little is known about other factors 
predictive of DS. A study by the European APL Group 
analyzed  prognostic  factors  of  DS  in  a  significant 
number of  patients  who  were  randomized  to  receive 
either  ATRA  followed  by  chemotherapy  or  both 
simultaneously.
6 That  study  did  not  reveal  any 
significant prognostic factors for DS in both treatment 
arms. This trial showed that patients with WBC count 
greater  than  5  ×  10
9/L  and  DS  tended  to  need 
mechanical ventilation more frequently than those with 
lower  WBC  counts,  but  this  was  not  statistically 
significant  and  the  baseline  WBC  count  was  not 
associated  with  the  development  of  DS. In  a 
PETHEMA study,
9 several pretreatment variables were 
predictive  of  the  severe  form  of  this  syndrome, 
including WBC count (> 5 × 10
9/L), abnormal serum 
creatinine  levels,  FLT3-ITD  mutation,  microgranular 
FAB subtype, short PML-RARA isoform (BCR3), and 
male  gender.  Multivariate  analysis  reduced  the 
significant  variables  to  WBC  counts  and  serum 
creatinine levels. Renal failure due to the capillary leak 
syndrome  caused  by  cytokine  release  in  DS  may 
explain the association between high serum creatinine 
and severe DS. In addition, WBC count (> 10 × 10
9/L), Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
lactate dehydrogenase greater than the upper laboratory 
normal values, and peripheral blood blasts greater than 
70%  were  significantly  associated  with  the 
development  of  moderate  DS.  Nevertheless,  none  of 
these prognostic factors have been confirmed in other 
studies  so  far,  and  they  should  be  cautiously 
interpreted.  Clinical  and  experimental  studies  have 
suggested an association between the development of 
DS and the expression of adhesion molecules such as 
CD13
11 and  CD11b.
27,28 A  large  PETHEMA 
trial9Errore.  Il  segnalibro  non  è  definito. could  not 
demonstrate such a relationship between the expression 
of  any  of  the  surface  markers  analyzed  and  the 
development of DS. On the other hand, results of a US 
Intergroup  study  indicated  that,  contrary  to  the 
PETHEMA study, the microgranular subtype of APL 
protected against the development of DS. Recently, a 
body mass index over 35 has been related to a higher 
incidence of DS,
29 but this finding still has not been 
confirmed in subsequent studies.
Only one study has analyzed the factors predicting 
fatal  outcome  of  DS.
30 This  study  found  that  bad 
performance status (ECOG score of at least 2) and low 
serum  level  of  albumin  were  the  only  prognostic 
factors  related  with  DS-associated  mortality.  These 
findings may reflect the vulnerability to the end-organ 
effects  of  the  DS  in  patients  with  prior  poor  health 
status. 
Management  of  the  DS.  The  early  addition  of 
chemotherapy  to  ATRA  and  the  administration  of 
high-dose dexamethasone at the onset of the first sign 
or  symptom  appear  to  have  reduced  the  mortality 
associated with this syndrome from 30%
1,11 to 5% or 
less  in  the  most  recent  trials  (Table  2).
6,8,9,10,25 It  is 
recommended  to  start  treatment  with  intravenous 
dexamethasone  at  a  dose  of  10  mg  twice  daily 
promptly  at  the  very  earliest  suspicion  of  DS.  Most 
patients  will  show  rapid  improvement  and  complete 
resolution  of  signs  and  symptoms  after  starting 
intravenous  dexamethasone.
31 Corticosteroids  therapy 
should be continued until the complete disappearance 
of symptoms and then tapered. In a few cases, a first 
episode  of  DS  resolved  with  corticosteroids  can  be 
followed  by  a  recurring  episode  of  DS  after  period 
without corticosteroids.
8 In such cases, dexamethasone 
should be resumed until resolution of the second wave 
of  DS.  The  common  short-term  toxic  effects  of 
dexamethasone  therapy  include  transient  diabetes, 
hypertension,  peptic  ulcer,  emotional  instability,  and 
increased risk of infections. The treatment of DS with 
dexamethasone  should  include  all  the  necessary 
medical  support  to  prevent  these  undesirable  side 
effects.
Whether  the  differentiation  agents  should  be 
discontinued  when  DS  takes  place  remains 
controversial.  It  seems  likely  that  both  ATRA  and 
ATO  can  be  safely  continued  in  the  majority  of 
patients with DS as long as intravenous dexamethasone 
has  been  started.  It  is  reasonable  to temporarily 
discontinue ATRA or  ATO  when  the  DS  progresses 
rapidly despite starting dexamethasone or when the DS 
is presented as a full-blown syndrome (i.e., severe DS) 
or with severe end-organ dysfunction (e.g., mechanical 
ventilation  or  dialysis  required).  Once  the  signs  and 
symptoms of severe DS are completely resolved, the 
differentiating agent should be restarted and continued 
until CR and/or the achievement of minimum length 
duration of differentiating therapy. In this regard, the 
study  by  Thépot  et  al,
32 suggested  that  the  total 
duration of therapy with ATRA of less than 21 days 
during the induction phase was associated with higher 
rates of leukemic relapse. It should be noted that this 
study  was  performed  in  patients  treated  with  the 
European APL93 and 2000 trials that did not include 
further  administration  of  intermittent  ATRA  during 
consolidation  phase.  Temporary  discontinuation  of 
ATRA was recommended in the PETHEMA protocols 
in  cases  where there  was  progression  of  the  clinical 
symptoms of DS or when the DS was considered life-
threatening. In the first PETHEMA study,
9 intravenous 
dexamethasone  was  administered  in  90%  of  patients 
with severe DS and 82% of patients with moderate DS, 
while ATRA was temporarily discontinued in 64% and 
60%  of  patients  with  severe  DS  and  moderate  DS, 
respectively.  In  the  second  PETHEMA  study,
10 
intravenous dexamethasone was administered in 83% 
and  ATRA  was  temporarily  discontinued  in  74%  of 
patients  developing  DS.  The  overall  mortality 
attributed to  DS  in  both  studies  was 1%, suggesting 
that the management of the syndrome was appropriate. 
Other  supportive measures  are  also  crucial  in  the 
correct  management  of  the  DS.  In  the  PETHEMA 
protocols, furosemide is usually administered to treat 
acute renal failure, peripheral and pulmonary edema, 
and  weight  gain.  Dialysis  or  venous  continuous 
ultrafiltration  is  needed  to  manage  some  cases  with 
refractory  acute  renal  failure  and/or  fluid  overload. 
Invasive, but also non-invasive, mechanical ventilation 
is  indicated  in  some  patients  with  severe  acute 
respiratory  failure  that  do  not  respond  to  high-flow 
oxygen  therapy.  In  PETHEMA  studies  diuretics, 
dialysis,  and  mechanical  ventilation  were  needed  in 
87%, 12%, and 26% of patients with DS, respectively. 
These  supportive  measures  were  more  frequently 
needed in patients with severe DS than in those with 
moderate DS. In addition, many patients will develop 
pre-renal failure and hypotension in the context of a 
vascular leak syndrome. In those cases, careful fluids 
and/or  vasopressor  agents,  in  conjunction  with Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
empirical therapy with  intravenous antibiotics should 
be implemented.
While the preemptive use of corticosteroids at the 
earliest clinical manifestations of DS has been adopted 
as  the  standard  treatment,
33 their  prophylactic  use  is 
more  controversial.  The  only  available  evidence 
supporting  the  use  of  corticosteroid  prophylaxis  is 
based  on  a  study  by  Wiley  and  Firkin
34 that  was 
performed  in  19  patients  treated  with  ATRA  alone. 
This study showed a reduction in pulmonary toxicity 
by administration of prednisone when the WBC count 
rose above 10 × 10
9/L. Based on these results, several 
trials have included prophylaxis with dexamethasone in 
patients with more than 5 to 10 × 10
9/L.
25,10 The impact 
of prophylactic strategies for the DS was assessed in 
three consecutive PETHEMA trials. In the LPA96 trial, 
patients  with  a  WBC  count  greater  than  5  ×  10
9/L 
(before  or  during  treatment  with  ATRA)  received 
prophylaxis  with  dexamethasone  (10  mg/12  hours 
intravenously for 7 days), resulting in an incidence of 
DS of 30%. In the LPA99 trial, all patients received DS 
prophylaxis with prednisone (0.5 mg/kg/d orally from 
days 1 to 15), and the incidence of DS was 23%. In the 
LPA2005 trial, only patients with WBC count greater 
than  5  ×  10
9/L  received  prophylaxis  with 
dexamethasone (2.5  mg/m2/12h  intravenously for  15 
days),  resulting  in  28%  of  DS.  The  retrospective 
comparison  of  these  trials  showed  an  apparent 
reduction in the incidence of DS, but not in DS-related 
mortality,
30 when a 0.5 mg/kg daily dose of prednisone 
during the first 15 days of induction therapy was given. 
Clinical  outcome  of  the  DS.  The  concomitant 
administration  of  chemotherapy  and  differentiating 
agents and the use of high-dose dexamethasone at the 
onset of the first symptoms appear to have reduced the 
DS-related mortality to 1% or less in the most recent 
trials,  compared  with  5%  to  9%  in  the  previously 
reported  studies  (Table  2).  It  is  likely  that  the 
development of moderate forms of DS has little impact 
on the death rate during induction therapy, whilst the 
severe DS seems associated with a higher death rate. In 
the  PETHEMA  series,
9 the  DS-associated  mortality 
was 11% in patients with severe DS, while no deaths 
resulted  from  moderate  DS.  Particularly,  the  DS-
associated  mortality  was  16%  in  patients  with  early 
severe  DS.  Interestingly,  the  haemorrhage-associated 
mortality was  also higher in  patients who developed 
severe DS. This  finding is in line with the study by 
Yanada  et  al,
35 suggesting  that  patients  with  DS  are 
more prone to develop severe haemorrhage during the 
induction phase. 
The  development  of  DS  may  have  additional 
implications, such as an increase in morbidity leading 
to an increased use of hospital resources. In this regard, 
the PETHEMA group showed that the forms of severe 
DS  leads  to  increased  morbidity  during  induction 
therapy.9Errore.  Il  segnalibro  non  è  definito. As  an 
example, the development of severe DS was associated 
with  a  higher  incidence  of  thrombosis  and 
coagulopathy, and to a higher use of plasma, platelet, 
and  red  blood  cell  transfusions  during  induction 
therapy. In fact,  an exacerbation of the procoagulant 
state of APL has been concurrently observed with the 
development of DS,
36-39  leading to an increased risk of 
haemorrhage and thrombosis. In addition, patients with 
severe DS spend more days in hospital and show grade 
3 or 4 hepatotoxicity during induction more frequently.
The European APL Group has reported an increased 
risk of relapse independent of WBC count in patients 
developing  DS.
7 This  interesting  finding  was 
confirmed  in  patients  developing  severe  DS  treated 
according the PETHEMA LPA96 trial, but not in those 
enrolled in the LPA99 trial. A possible explanation is 
that  in  the  LPA96  trial  most  of  the  patients  who 
developed  severe  DS  received  lower  total  dose  of 
ATRA,
32 since ATRA was frequently discontinued as 
part of the management of the DS. In contrast, patients 
enrolled in the LPA99 trial received additional ATRA 
for  consolidation,  which  may  counterbalance  the 
reduction  of  total  dosage  of  ATRA  for  induction
therapy  in  patients  developing  severe  DS.  We  can 
hypothesize  that  the  addition  of  ATRA  during 
consolidation therapy could be beneficial for reducing 
the  risk  of  relapse,  especially  in  those  patients 
developing severe DS who had received only reduced 
doses of ATRA during induction. On the other hand, 
some authors have speculated about an increased risk 
of extramedullary relapse, in particular in the central 
nervous  system,  in  patients  developing  DS.
6,40
However, this association has not been confirmed in 
larger series.
9,41
Conclusions.  Roughly  one  quarter  of  patients  with 
APL  undergoing  induction  therapy  will  develop  DS.
The early administration of high-dose dexamethasone 
at the onset of the first signs or symptoms of DS is 
crucial,  since  it  appears  to  dramatically  reduce 
mortality  of  this  complication.  The  etiopathogenic 
mechanisms  of  this  life-threatening  complication  are 
complex  and  remain  partially  unknown.  Specific 
biological therapies to counteract the syndrome are still 
not  available.  Randomized  studies  are  required  to 
ascertain  whether  or  not  the  use  of  corticosteroid 
prophylaxis  is  advantageous,  particularly  taking  into 
account  that  infectious  mortality  is  not  apparently 
increased when prednisone prophylaxis is used.
30 Risk-
adapted prophylactic and therapeutic strategies based 
on the adverse risk factors for development of severe 
DS (e.g., WBC counts > 5 × 10
9/L or abnormal levels Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
of serum creatinine) require further research. 
References: 
1. Frankel  SR,  Eardley  A,  Lauwers  G,  Weiss  M,  Warrell R.  The 
‘retinoic  acid  syndrome’  in  acute  promyelocytic  leukemia.  Ann 
Intern Med 1992; 117: 292. PMid:1637024
2. Luesink M, Pennings JL, Wissink WM, et al. Chemokine induction 
by  all-trans  retinoic  acid  and  arsenic  trioxide  in  acute 
promyelocytic  leukemia: triggering  the differentiation  syndrome. 
Blood  2009;  114:5512. http://dx.doi.org/10.1182/blood-2009-02-
204834 PMid:19828696
3. Frankel SR, Eardley A, Heller G, et al. All-trans retinoic acid for 
acute  promyelocytic  leukemia.  Results  of  the  New  York  Study. 
Ann Intern Med 1994; 120:278. PMid:8291820
4. Nicolls  MR,  Terada  LS,  Tuder  RM,  et  al.  Diffuse  alveolar 
hemorrhage with underlying pulmonary capillaritis in the retinoic 
acid  syndrome.  Am  J  Respir  Crit  Care  Med  1998;  158:1302.
PMid:9769296
5. Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in 
PML/RAR  alpha-positive  acute  promyelocytic  leukemia  by 
combined all-trans  retinoic acid  and  idarubicin  (AIDA) therapy. 
Gruppo  Italiano-Malattie Ematologiche  Maligne  dell'Adulto  and 
Associazione  Italiana  di  Ematologia  ed  Oncologia  Pediatrica 
Cooperative Groups. Blood. 1997;90:1014–1021. PMid:9242531
6. De  Botton  S,  Dombret  H,  Sanz  M,  et  al.  Incidence,  clinical 
features, and outcome of all trans-retinoic acid syndromes in 413 
cases of newly diagnosed  acute promyelocytic  leukemia.  Blood. 
1998;92:2712–2718. PMid:9763554
7. De  Botton  S,  Chevret  S,  Coiteux V,  et  al.  Early  onset  of 
chemotherapy  can  reduce  the  incidence  of  ATRA  syndrome  in 
newly  diagnosed  acute promyelocytic  leukemia  (APL)  with  low 
white  blood  cell  counts:  results  from  APL  93  trial.  Leukemia. 
2003;17:339–342. http://dx.doi.org/10.1038/sj.leu.2402807
PMid:12592333
8. Tallman MS, Andersen JW, Schiffer CA, et al. Clinical description 
of 44 patients with acute promyelocytic leukemia who developed 
the  retinoic  acid  syndrome.  Blood.  2000;95:90–95.
PMid:10607690
9. Montesinos  P,  Bergua  JM,  Vellenga  E,  et  al.  Differentiation 
syndrome  in  patients  with acute promyelocytic  leukemia  treated 
with  all-trans  retinoic  acid  and  anthracycline  chemotherapy: 
characteristics,  outcome,  and  prognostic  factors.  Blood  2009; 
113:775. http://dx.doi.org/10.1182/blood-2008-07-168617
PMid:18945964
10. Sanz MA, Montesinos P, Rayón C, et al. Risk-adapted treatment of 
acute promyelocytic leukemia based on all-trans retinoic acid and 
anthracycline with addition of cytarabine in consolidation therapy 
for  high-risk  patients:  further  improvements  in  treatment 
outcome.Blood.  2010  Jun  24;115(25):5137-46.
http://dx.doi.org/10.1182/blood-2010-01-266007 PMid:20393132
11. Vahdat L, Maslak P, Miller WH Jr, et al. Early mortality and the 
retinoic acid syndrome in acute promyelocytic leukemia: impact of 
leukocytosis,  low-dose  chemotherapy,  PMN/RAR-alpha  isoform, 
and CD13 expression in patients treated with all-trans retinoic acid. 
Blood. 1994;84:3843–3849. PMid:7949141
12. Jung JI, Choi JE, Hahn ST, et al. Radiologic features of all-trans-
retinoic  acid  syndrome.  AJR  Am  J  Roentgenol  2002;  178:475.
PMid:11804921
13. Flombaum  CD,  Isaacs  M,  Reich  L,  et  al.  Acute  renal  failure 
associated with the retinoic acid syndrome in acute promyelocytic 
leukemia.  Am  J  Kidney  Dis  1996;  27:134.
http://dx.doi.org/10.1016/S0272-6386(96)90041-4
14. Camacho LH, Soignet SL, Chanel S, et al. Leukocytosis and the 
retinoic  acid  syndrome  in  patients  with  acute  promyelocytic 
leukemia treated with arsenic trioxide. J Clin Oncol 2000; 18:2620.
PMid:10893295
15. Raanani P, Segal E, Levi I, et al. Diffuse alveolar hemorrhage in 
acute  promyelocytic  leukemia  patients  treated  with  ATRA--a 
manifestation  of  the  basic  disease  or  the  treatment.  Leuk 
Lymphoma  2000;  37:605.
http://dx.doi.org/10.3109/10428190009058513
16. De Santis GC, Madeira MI, de Oliveira LC, Falcao RP, Rego EM. 
Cardiac  stunning  as  a  manifestation  of  ATRA  differentiation 
syndrome in acute promyelocytic leukemia. Med Oncol. 2011 Jan 
26.
17. Kanamaru A, Takemoto Y, Tanimoto M, et al. All-trans retinoic 
acid  for  the  treatment  of  newly  diagnosed  acute  promyelocytic 
leukemia. Japan Adult Leukemia Study Group. Blood 1995 Mar 
1;85(5):1202-6. PMid:7858250
18. Cortes JE,  Kantarjian  H,  O'Brien  S,  et  al.All-trans  retinoic  acid 
followed  by  chemotherapy  for  salvage  of  refractory or  relapsed 
acute promyelocytic leukemia. Cancer. 1994 Jun 15;73(12):2946-
52. http://dx.doi.org/10.1002/1097-
0142(19940615)73:12<2946::AID-CNCR2820731211>3.0.CO;2-
Q
19. Avvisati G, Lo Coco F, Diverio D, et al. AIDA (all-trans retinoic 
acid  +  idarubicin)  in  newly  diagnosed  acute  promyelocytic 
leukemia:  a  Gruppo  Italiano  Malattie  Ematologiche  Maligne 
dell'Adulto  (GIMEMA)  pilot  study.  Blood.  1996  Aug 
15;88(4):1390-8. PMid:8695858
20. Mathews  V,  George  B,  Chendamarai  E,  Single-Agent  Arsenic 
Trioxide  in  the  Treatment  of  Newly  Diagnosed  Acute 
Promyelocytic Leukemia: Long-Term Follow-Up Data. JCO 2010 
August  15;  28(24):  3866-3871
http://dx.doi.org/10.1200/JCO.2010.28.5031 PMid:20644086
21. Ghavamzadeh  A,  Alimoghaddam  K,  Rostami S,  et  al.  Phase  II 
study of single-agent arsenic trioxide for the front-line therapy of 
acute  promyelocytic  leukemia.  J  Clin  Oncol.  2011  Jul 
10;29(20):2753-7. http://dx.doi.org/10.1200/JCO.2010.32.2107
PMid:21646615
22. Liu YF, Shen ZX, Chen X, et al. Clinical observation of the short-
term efficacy of the treatment with combination of all-trans retinoic 
acid  (ATRA)  and  arsenic  trioxide  (As2O3)  in  newly  diagnosed 
acute promyelocytic leukemia (APL). Zhonghua Xue Ye Xue Za 
Zhi. 2003 Jan;24(1):25-7. PMid:12679006
23. Ravandi  F,  Estey  E,  Jones  D,  et  al.  ffective  treatment  of  acute 
promyelocytic  leukemia  with  all-trans-retinoic  acid,  arsenic 
trioxide, and gemtuzumab ozogamicin. J Clin Oncol 27:504–510.
http://dx.doi.org/10.1200/JCO.2008.18.6130 PMid:19075265
24. Lengfelder  E,  Lo-Coco  F,  Montesinos  P,  et  al.  Treatment  of 
Molecular and Clinical Relapse of Acute Promyelocytic Leukemia 
(APL) with Arsenic Trioxide: Results of the European Registry of 
Relapsed APL ASH Annual Meeting Abstracts 2010 116:15
25. Adès L, Chevret S, Raffoux E, et al. Is cytarabine useful in the 
treatment  of  acute  promyelocytic  leukemia?  Results  of  a 
randomized trial from the European Acute Promyelocytic Group. J 
Clin  Oncol.  2006;24:5703–5710.
http://dx.doi.org/10.1200/JCO.2006.08.1596 PMid:17116939
26. Lengfelder  E,  Reichert  A,  Schoch  C,  et  al.  Double  induction
strategy including high dose cytarabine in combination with all-
trans retinoic acid: Effects in patients with newly diagnosed acute 
promyelocytic  leukemia—German  AML  Cooperative  Group. 
Leukemia.  2000;14:1362–1370.
http://dx.doi.org/10.1038/sj.leu.2401843 PMid:10942230
27. Wu  JJ,  Cantor  A,  Moscinski  LC.  Beta2  Integrins  are 
characteristically  absent  in  acute  promyelocytic  leukemia  and 
rapidly  upregulated  in  vivo  upon  differentiation  with  all-trans 
retinoic  acid.  Leuk  Res.  2007;31:49–57.
http://dx.doi.org/10.1016/j.leukres.2006.04.012 PMid:16764927
28. Cunha De Santis G, Tamarozzi MB, et al. Adhesion molecules and 
Differentiation  Syndrome: phenotypic  and  functional  analysis  of 
the effect of ATRA, As2O3, phenylbutyrate, and G-CSF in acute 
promyelocytic  leukemia.  Haematologica.  2007;92:1615–22.
http://dx.doi.org/10.3324/haematol.10607 PMid:18055984
29. Jeddi R, Ghédira H, Mnif S, et al. High body mass index is an 
independent predictor of differentiation syndrome in patients with 
acute  promyelocytic  leukemia.  Leuk  Res  2010;  34:545.
http://dx.doi.org/10.1016/j.leukres.2009.09.017 PMid:19800119
30. de  la  Serna  J,  Montesinos  P,  Vellenga  E,  et  al:  Causes  and 
prognostic factors of remission induction failure in patients with 
acute promyelocytic leukemia treated with all-trans retinoic acid Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
and  idarubicin.  Blood  111:3395–3402,  2008
http://dx.doi.org/10.1182/blood-2007-07-100669 PMid:18195095
31. Patatanian E, Thompson DF. Retinoic acid syndrome: a review. J 
Clin  Pharm  Ther  2008;  33:331. http://dx.doi.org/10.1111/j.1365-
2710.2008.00935.x PMid:18613850
32. Thepot S, Gardin C, Chevret S, et al, Impact of ATRA Duration 
during the Induction Treatment of Newly Diagnosed APL.  ASH 
Annual Meeting Abstracts 2008 112:139
33. Sanz MA, Grimwade D, Tallman MS, et al. Management of acute 
promyelocytic leukemia: recommendations from an  expert panel 
on behalf of the European LeukemiaNet. Blood 2009; 113:1875.
http://dx.doi.org/10.1182/blood-2008-04-150250 PMid:18812465
34. Wiley  JS,  Firkin  FC.  Reduction  of  pulmonary  toxicity  by 
prednisolone prophylaxis during all-trans retinoic acid treatment of 
acute promyelocytic leukemia. Australian Leukaemia Study Group. 
Leukemia. 1995;9:774–778. PMid:7769839
35. Yanada  M,  Matsushita  T,  Asou N,  et  al.  Severe  hemorrhagic 
complications  during  remission  induction  therapy  for  acute 
promyelocytic leukemia: incidence, risk factors, and influence on 
outcome.  Eur  J  Haematol.  2007;78:213–219.
http://dx.doi.org/10.1111/j.1600-0609.2006.00803.x
PMid:17241371
36. Larson  RS,  Brown  DC,  Sklar  LA.  Retinoic  acid  induces 
aggregation of the acute promyelocytic leukemia cell line NB-4 by 
utilization  of  LFA-1  and  ICAM-2.  Blood.  1997;90:2747–2756.
PMid:9326242
37. Di Noto R, Schiavone EM, Ferrara F et al. All-trans retinoic acid 
promotes a differential regulation of adhesion molecules on acute 
myeloid  blast  cells.  Brit  J  Haematol.  1996;88:247–255.
http://dx.doi.org/10.1111/j.1365-2141.1994.tb05014.x
PMid:7803267
38. Tallman  MS,  Lefèbvre  P,  Baine  RM,  et  al.  Effects  of  all-trans 
retinoic  acid  or  chemotherapy  on  the  molecular  regulation  of 
systemic blood coagulation and fibrinolysis in patients with acute 
promyelocytic leukemia. J Thromb Haemost. 2004;2:1341–1350.
http://dx.doi.org/10.1111/j.1538-7836.2004.00787.x
PMid:15304040
39. Falanga  A,  Rickles  FR.  Pathogenesis  and  management  of  the 
bleeding  diathesis  in  acute promyelocytic  leukaemia.  Best  Pract 
Res  Clin  Haematol.  2003;16:463–482.
http://dx.doi.org/10.1016/S1521-6926(03)00059-8
40. Ko BS, Tang JL, Chen YC, Yao Met al. Extramedullary relapse 
after  all-trans  retinoic  acid  treatment  in  acute  promyelocytic 
leukemia—the  occurrence  of  retinoic  acid  syndrome  is  a  risk 
factor.  Leukemia.  1999;13:1406–1408.
http://dx.doi.org/10.1038/sj.leu.2401495 PMid:10482992
41. Montesinos P, Díaz-Mediavilla J, Debén G, et al. Central nervous 
system  involvement  at  first  relapse  in  patients  with  acute 
promyelocytic  leukemia  treated  with  all-trans  retinoic  acid  and 
anthracycline monochemotherapy without intrathecal prophylaxis. 
Haematologica.  2009  Sep;94(9):1242-9.
http://dx.doi.org/10.3324/haematol.2009.007872 PMid:19608685 
PMCid:2738716